The global race to find better treatments for type 2 diabetes and obesity — a race that GLP-1 receptor agonists like Ozempic, Wegovy, Mounjaro, and Zepbound have dominated for the past four years — has produced a potentially important new contender. Researchers at Karolinska Institutet and Stockholm University published findings June 3, 2026 in the journal Cell describing an experimental oral medication that works through an entirely different mechanism than GLP-1 drugs: rather than suppressing appetite by mimicking gut hormones, it directly activates metabolism inside skeletal muscle, increasing fat burning and improving blood sugar control while preserving lean mass.

The distinction is clinically significant. GLP-1 drugs are highly effective, but their well-documented side effects — persistent nausea, gastrointestinal distress, and muscle wasting (which can occur when weight loss happens faster than the body can preserve lean mass) — have driven substantial demand for alternatives, particularly for patients who cannot tolerate GLP-1s or who specifically want to maintain muscle mass during metabolic treatment.

"Our results point to a future where we can improve metabolic health without losing muscle mass," said Professor Tore Bengtsson, of the Wenner-Gren Institute at Stockholm University. "Muscles are important in both type 2 diabetes and obesity, and muscle mass is also directly correlated with life expectancy."

How the New Drug Works

The experimental compound is a next-generation selective beta-2 agonist. Beta-2 adrenergic receptors in skeletal muscle regulate metabolic activity; when activated, they increase the muscle's rate of fat oxidation and glucose uptake. Traditional beta-2 agonists — used historically in asthma inhalers — produced cardiovascular side effects that limited their use for metabolic conditions. The new compound is engineered to selectively activate muscle metabolism while sparing cardiac tissue, addressing the historical safety concern that blocked this pathway's development.

In animal models, the drug improved blood sugar control and body composition — more fat loss, preserved lean muscle — compared to untreated controls. When combined with GLP-1 drugs in animal models, it specifically counteracted the muscle loss that GLP-1s can produce, suggesting a potential for combination therapy that delivers the appetite suppression of a GLP-1 plus the muscle-preserving metabolic activation of the new compound.

The early human clinical trial, involving 48 healthy adults and 25 people with type 2 diabetes, confirmed the compound was safe and well-tolerated with pharmacokinetic properties suitable for once-daily oral dosing. Larger phase II efficacy trials are the next step.

What It Means for the 42 Percent of Americans with Obesity

More than 42 percent of American adults have obesity, and approximately 37 million have type 2 diabetes — populations for whom metabolic medications have the potential to dramatically reduce long-term chronic disease burden. GLP-1 drugs have expanded the treatment landscape but remain inaccessible for many patients due to cost, insurance coverage, or side effect intolerance. A muscle-targeted oral pill, if it advances through clinical development, would offer a new and potentially complementary therapeutic option — particularly for older adults and physically active individuals for whom preserving muscle mass is both a functional and longevity priority.

Read more

Frequently Asked Questions

Q: How is this new pill different from Ozempic?

A: Ozempic and other GLP-1 drugs work by suppressing appetite through gut-brain hormone signaling. The new compound directly activates metabolism in skeletal muscle, increasing fat burning and blood sugar uptake without reducing hunger or causing muscle loss.

Q: Has it been tested in humans?

A: Yes. A Phase I trial in 48 healthy adults and 25 people with type 2 diabetes confirmed it was safe and well-tolerated, with appropriate pharmacokinetics for once-daily dosing. Larger efficacy trials are planned.

Q: When will it be available?

A: The drug is in early clinical development. Typically, 5–7 years of additional Phase II/III trials and regulatory review are needed before approval.

Q: Could it be used with GLP-1 drugs like Ozempic?

A: Animal studies suggest the compound can counteract muscle loss caused by GLP-1 drugs when used in combination, pointing toward potential combination therapy. Human combination studies have not yet been conducted.